Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.

Blanca Hernández Cruz Lucia Otero VarelaMercedes Freire-GonzálezNoemí Busquets Pérez Alfredo Javier García González Manuel José Moreno-RamosJuan Maria Blanco-MadrigalSara Manrique Arija Eva Perez-Pampin María Dolores Ruiz-MontesinoFernando Sánchez-AlonsoCarlos Sánchez-Piedra Isabel Castrejonnull null

Published in: Annals of the rheumatic diseases (2024)

Infections, herpes zoster and gastrointestinal adverse events in patients with RA tended to be more frequent with JAKi. However, prognosis was poor in patients receiving JAKi. Persistence was similar for TNFi and JAKi, although factors associated with discontinuation differed by diagnostic group.

Keyphrases

rheumatoid arthritis
disease activity
ankylosing spondylitis
systemic lupus erythematosus
electronic health record
interstitial lung disease
big data
deep learning